

# CANCER GENOMICS & PROTEOMICS

**Published by the International Institute of Anticancer Research**

ISSN (print): 1109-6535; ISSN (online): 1790-6245

**Volume 15, 2018**

**INDEX**

## Editorial Board

<b>A. Seth</b>	Editor-in-Chief Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
<b>G.J. Delinasios</b>	Managing Editor and Executive Publisher International Institute of Anticancer Research, Athens, Greece
<b>L.A. Aaltonen</b>	Department of Medical Genetics, University of Helsinki, Finland
<b>R. Abagyan</b>	The Scripps Research Institute, La Jolla, CA, USA
<b>F. Ahmed</b>	Department of Radiation Oncology, East Carolina University School of Medicine, Greenville, NC, USA
<b>D.-T. Bau</b>	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
<b>R. Clarke</b>	Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
<b>T. Efferth</b>	Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
<b>N.A. Ellis</b>	Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
<b>J.A. Fernandes-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>C.V. Forst</b>	Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
<b>D.S. Gerhard</b>	NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
<b>G. Glinsky</b>	Institute of Engineering in Medicine, University of California, San Diego, CA, USA
<b>T.R. Golub</b>	Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
<b>J. Gordon</b>	Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
<b>C.-H. Heldin</b>	Ludwig Institute for Cancer Research, Uppsala, Sweden
<b>J.D. Hoheisel</b>	Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
<b>T.H.M. Huang</b>	Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
<b>S.C. Jhanwar</b>	Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
<b>W.G. Jiang</b>	Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, UK
<b>J. Ju</b>	Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
<b>A. Kallioniemi</b>	Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
<b>O.P. Kallioniemi</b>	Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
<b>K. Khalili</b>	College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
<b>D.G. Kieback</b>	Helios Medical Center Schleswig, Schleswig, Germany
<b>S.D. Kottaridis</b>	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
<b>Y. T. Kwon</b>	Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea
<b>B. Léylard-Jones</b>	Avera Cancer Institute, Sioux Falls, SD, USA
<b>P. Lichter</b>	Deutsches Krebsforschungszentrum, Heidelberg, Germany
<b>A. Lindblom</b>	Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
<b>G. Lubec</b>	Department of Pediatrics, University of Vienna, Austria
<b>J. Lyons-Weiler</b>	Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
<b>P.J. McCormick</b>	The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
<b>F. Mitelman</b>	Department of Clinical Genetics, University Hospital, Lund, Sweden
<b>C. Nicot</b>	Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
<b>L. O'Driscoll</b>	School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
<b>C.D. Platsoucas</b>	College of Sciences, Old Dominion University, Norfolk, VA, USA
<b>J. Quackenbush</b>	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA

<b>J.S. Rader</b>	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
<b>R.H. Reeves</b>	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
<b>K.L. Reichelt</b>	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
<b>T. Ried</b>	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
<b>G. Rimbach</b>	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
<b>K.D. Rodland</b>	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
<b>C. Sansom</b>	The School of Crystallography, Birbeck College, University of London, UK
<b>N.A. Saunders</b>	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
<b>B.W. Schäfer</b>	Department of Oncology, University Children's Hospital, Zurich, Switzerland
<b>J. Schneider</b>	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
<b>O.J. Semmes</b>	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
<b>G.V. Sherbet</b>	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
<b>S. Smith</b>	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
<b>J.C. Strefford</b>	Cancer Science Division, Southampton General Hospital, Southampton, UK
<b>J.M. Trent</b>	Tgen, Phoenix, AZ, USA
<b>G. Tsangaris</b>	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
<b>U.H. Weidle</b>	Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
<b>A.T. Yeung</b>	Fox Chase Cancer Center, Philadelphia, PA, USA
<b>H. Zhang</b>	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, MEDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; Science Citation Index Expanded (Web of Science); Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. Web: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.cgp.iiarjournals.org](http://www.cgp.iiarjournals.org).

**Editorial Office in U.S.A.:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlights, NJ 07732, USA.

E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Managing Editor: [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org).

Web: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); <http://cgp.iiarjournals.org>.

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org)

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

## Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 15, 2018.

- AstraZeneca, Cambridge, U.K.
- Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
- Biomedical Research Institute Grant, Kyungpook National University Hospital, Daegu, Republic of Korea
- Breast Cancer Hope Foundation, London, U.K.
- Canadian Breast Cancer Foundation, Canada
- CancerCare Manitoba Foundation (CCMF), Winnipeg, MB, Canada
- Chulabhorn Graduate Institute, Bangkok, Thailand
- Chulabhorn Research Institute, Bangkok, Thailand
- Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- College of Pharmacy and Pharmaceutical Sciences, Florida A & M University, Tallahassee, FL, U.S.A.
- Czech Science Foundation, Czech Republic
- Danish Cancer Society, Copenhagen, Denmark
- Department of Biology, Florida A&M University, Tallahassee, FL, U.S.A.
- Division of Translational Research, Exploratory Oncology and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan
- Editage, Japan
- Elite Network of Bavaria, Munich, Germany
- EOGE (Society of Oncological Research) Oncology Research Fund, Patras, Greece
- Gavin Bailey Tissue Repository for Neural Crest Disorders, Bartlesville, OK, U.S.A.
- German Academic Exchange Service (DAAD), Bonn, Germany
- Global Research Laboratory (GRL) Program, Republic of Korea
- Graduate School Research Program, Juntendo University, Tokyo, Japan
- Grant of Translational R&D Project, Institute for Bio-Medical Convergence, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea
- Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
- Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
- Hellenic Society of Medical Oncology (HeSMO), Athens, Greece
- Institute of Biomathematics, Faculty of Medicine, Mannheim, Germany
- Iuventus Plus Program, Polish Ministry of Science and Higher Education, Warsaw, Poland
- Jagiellonian University, Krakow, Poland.
- Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
- Korea Brain Research Institute (KBRI) Basic Research Program, Daegu, Republic of Korea
- Larvik Kreftforening, Larvik, Norway
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
- Ministry of Health of the Czech Republic, Prague, Czech Republic
- Ministry of Science and ICT (MSIT), Gwacheon, Republic of Korea
- Moffitt Skin Cancer SPORE, Career Enhancement Program (CEP), Tampa, FL, U.S.A.
- National Cancer Center Research and Development Fund, Tokyo, Japan
- National Cancer Center, Seoul, Republic of Korea
- National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, Bethesda, MD, U.S.A.
- National Institute of Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Bethesda, MD, U.S.A.
- National Institutes of Health (NIH), Bethesda, MD, U.S.A.
- National Research Foundation of Korea (NRF) Grant, Ministry of Science, ICT & Future Planning (MSIP), Republic of Korea
- New Directions Research Collaboration Initiation Grant, Faculty of Science Interdisciplinary, University of Manitoba, Winnipeg, MB, Canada
- Norwegian Radium Hospital Research Foundation, Lysaker, Norway

Practical Research for Innovative Cancer Control Grant,  
Japan Agency for Medical Research and Development  
(AMED), Tokyo, Japan

Radiumhospitalets Legater, Oslo, Norway

Research Institute for Diseases of Old Age, Juntendo  
University, Tokyo, Japan

Research Support Center, Research Center for Human  
Disease Modeling, Kyushu University Graduate School  
of Medical Sciences, Fukuoka, Japan

Roche Hellas SA, Athens, Greece

Summer Student Research Fund, Research Institute of  
Oncology and Hematology, CancerCare Manitoba,  
Winnipeg, MB, Canada

Taichung Armed Forces General Hospital, Taichung,  
Taiwan, R.O.C.

Taichung Veterans General Hospital, Taichung, Taiwan,  
R.O.C.

Takeda Science Foundation, Japan

Tissue Bank, China Medical University, Taichung, Taiwan  
R.O.C.

Tissue Core Facility, H. Lee Moffitt Cancer Center &  
Research Institute, Tampa, FL, U.S.A.

University of Bergen, Bergen, Norway

University of Patras, Patras, Greece

## Contents, Volume 15, 2018

### Number 1, January-February

- \* Review: Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, A. NOPORA (*Penzberg, Germany; Basel, Switzerland*) ..... 1
- \* Review: The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOPF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZELE, U. BRINKMANN (*Penzberg; Munich, Germany; Basel, Switzerland*)..... 17
- \* Review: Applications of Support Vector Machine (SVM) Learning in Cancer Genomics. S. HUANG, N. CAI, P. PENZUTI PACHECO, S. NARANDES, Y. WANG, W. XU (*Winnipeg, Canada*)..... 41
- Regulation of  $\beta$ -Catenin Phosphorylation by PR55 $\beta$  in Adenoid Cystic Carcinoma. K. ISHIBASHI, K. ISHII, G. SUGIYAMA, Y. KAMATA, A. SUZUKI, W. KUMAMARU, Y. OHYAMA, H. NAKANO, T. KIYOSHIMA, T. SUMIDA, T. YAMADA, Y. MORI (*Fukuoka, Japan*) ..... 53
- Consistent Involvement of Chromosome 13 in Angiolipoma. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (*Oslo, Norway*) ..... 61
- Genetic Variations in the 3'-untranslated Regions of Genes Involved in the Cell Cycle and Apoptosis Pathways Affect Bladder Cancer Risk. Q. ZHANG, W. WANG, W. XU, M. DU, G. MA, H. LIU, H. CHU, N. TONG, M. WANG, J. SHAO, Z. ZHANG, L. YUAN, J. QIAN (*Nanjing; Beijing; Yizheng; Wuxi, PR China*) ..... 67
- 2-Methoxyestradiol Affects Mitochondrial Biogenesis Pathway and Succinate Dehydrogenase Complex Flavoprotein Subunit A in Osteosarcoma Cancer Cells. M. GORSKA-PONIKOWSKA, A. KUBAN-JANKOWSKA, S.A. EISLER, U. PERRICONE, G. LO BOSCO, G. BARONE, S. NUSSBERGER (*Gdansk, Poland; Stuttgart, Germany; Palermo, Italy*) ..... 73

### Number 2, March-April

- Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5. E. KJELDSEN, C.J.F. NIELSEN, A. ROY, C. TESAURO, A.-K. JAKOBSEN, M. STOUGAARD, B.R. KNUDSEN (*Aarhus, Denmark*) ..... 91
- Novel Germline *PTEN* Mutation Associated with Cowden Syndrome and Osteosarcoma. C. LOPEZ, M. ABUEL-HAIJA, L. PENA, D. COPPOLA (*Ponce, PR; Tampa, FL, USA*)..... 115
- Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. M.O. HUSSAINI, A.-S. MIRZA, R. KOMROKJI, J. LANCET, E. PADRON, J. SONG (*Tampa, FL, USA*) ..... 121
- ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance. D. TSOUMAS, S. NIKOU, E. GIANNOPOULOU, S. CHAMPERIS TSANIRAS, C. SIRINIAN, I. MAROULIS, S. TARAVIRAS, V. ZOLOTA, H.P. KALOFONOS, V. BRAVOU (*Patras, Greece*)..... 127
- LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression. P. WHONGSIRI, C. PIMRATANA, U. WIJITSETTAKUL, D. JINDATIP, A. SANPAVAT, W.A. SCHULZ, M.J. HOFFMANN, W. GOERING, C. BOONLA (*Bangkok; Buriram, Thailand; Düsseldorf, Germany*) ..... 143
- Review: Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. D. MORIS, I. NTANANIS-STATHOPOULOS, D.I. TSILIMIGRAS, M.A. ADAM, C.J. YANG, D. HARPOLE, S. THEOCHARIS (*Durham, NC, USA; Athens, Greece*) ..... 153

**Number 3, May-June**

Chromatin Immunoprecipitation and DNA Sequencing Identified a LIMS1/ILK Pathway Regulated by LMO1 in Neuroblastoma. N. SAEKI, A. SAITO, Y. SUGAYA, M. AMEMIYA, H. ONO, R. KOMATSUZAKI, K. YANAGIHARA, H. SASAKI (*Tokyo; Chiba, Japan*)..... 165

HIF-1 $\alpha$  and mTOR – Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC. B. KRAMER, M. POLIT, R. BIRK, N. ROTTER, C. ADERHOLD (*Mannheim; Marburg, Germany*) ..... 175

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. B.D. WILSON, L.J. RICKS-SANTI, T.E. MASON, M. ABBAS, R.A. KITTLES, G.M. DUNSTON, Y.M. KANAAN (*Washington, DC; Hampton, VA; Duarte, CA, USA*)..... 185

Cytogenetics of Spindle Cell/Pleomorphic Lipomas: Karyotyping and FISH Analysis of 31 Tumors. I. PANAGOPOULOS, L. GORUNOVA, M. LUND-IVERSEN, K. ANDERSEN, H.K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (*Oslo, Norway*) ..... 193

EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas. K.G. NEILL, J. SALLER, S. AL DIFFALHA, B.A. CENTENO, M.P. MALAFA, D. COPPOLA (*Tampa, FL, USA*)..... 201

The Contribution of *MMP-7* Genotypes to Colorectal Cancer Susceptibility in Taiwan. T.-C. YUEH, C.-N. WU, Y.-W. HUNG, W.-S. CHANG, C.-K. FU, J.-S. PEI, M.-H. WU, Y.-L. LAI, Y.-M. LEE, S.-T. YEN, H.-T. LI, C.-W. TSAI, D.-T. BAU (*Taichung; Taipei; Taoyuan, Taiwan, ROC*) ..... 207

Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline. T. TAKIMOTO-SHIMOMURA, H. NAGOSHI, S. MAEGAWA, Y. FUJIBAYASHI, T. TSUKAMOTO, Y. MATSUMURA-KIMOTO, Y. MIZUNO, Y. CHINEN, S. MIZUTANI, Y. SHIMURA, S. HORIIKE, M. TANIWAKI, T. KOBAYASHI, J. KURODA (*Kyoto; Hiroshima, Japan; Parkville, Australia*)..... 213

**Number 4, July-August**

\* Review: Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter  $\alpha$ -Trypsin Inhibitors. U.H. WEIDLE, F. BIRZELE, G. TIEFENTHALER (*Penzberg, Germany; Basel, Switzerland*) ..... 225

The Dual PI3K/mTOR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis. D. BASU, C.M. SALGADO, B. BAUER, Y. KHAKOO, J.R. PATEL, R.M. HOEHL, D.M. BERTOLINI, J. ZABEC, M.R. BRZOZOWSKI, M. REYES-MÚGICA (*Pittsburgh, PA; Northbrook, IL; New York, NY, USA*) ..... 239

Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response. E.A. MAZZIO, C.A. LEWIS, R. ELHAG, K.F. SOLIMAN (*Tallahassee, FL, USA*) ..... 249

Frequency of Mismatch Repair Protein Deficiency in a Puerto Rican Population with Colonic Adenoma and Adenocarcinoma. D. REVERÓN, C. LÓPEZ, S. GUTIÉRREZ, Z.E. SAYEGH, T. ANTONIA, J. DUTIL, M. MALAFA, D. COPPOLA (*Ponce, PR; Tampa, FL, USA*) ..... 265

Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the *SGK1* Gene Are Associated with Poorer Survival. S. LEHRER, P.H. RHEINSTEIN, K.E. ROSENZWEIG (*New York, NY, USA*) ..... 273

Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics. O.K. KWON, J.M. JEON, E. SUNG, A.-Y. NA, S.J. KIM, S. LEE (*Daegu, Republic of Korea*)..... 279

Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. J. JEON, L.-S. MAENG, Y.J. BAE, E.-J. LEE, Y.C. YOON, N. YOON ( <i>Incheon, Republic of Korea</i> ) .....	291
Identification and Quantification of Heterogeneously-methylated DNA Fragments Using Epiallele-sensitive Droplet Digital Polymerase Chain Reaction (EAST-ddPCR). M. MENSCHIKOWSKI, C. JANDECK, M. FRIEDEMANN, S. RICHTER, D. THIEM, B.S. LANGE, M. SUTTORP ( <i>Dresden, Germany</i> ).....	299
Overexpression of <i>FGFR1</i> Promotes Peritoneal Dissemination Via Epithelial-to-Mesenchymal Transition in Gastric Cancer. D. SHIMIZU, T. SAITO, S. ITO, T. MASUDA, J. KURASHIGE, Y. KURODA, H. EGUCHI, Y. KODERA, K. MIMORI ( <i>Tsurumihara; Nagoya; Kumamoto, Japan</i> ).....	313
Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection. P. KARASEK, N. GABLO, J. HLAVSA, I. KISS, P. VYCHYTILOVA-FALTEJSKOVA, M. HERMANOVA, Z. KALA, O. SLABY, V. PROCHAZKA ( <i>Brno, Czech Republic</i> ) .....	321
Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. E. FIEDOR, K. ZAJDA, E.L. GREGORASZCZUK ( <i>Krakow, Poland</i> ) .....	329
Proteomic Analysis of Pelvic Autonomic Nerve in Nerve-sparing Radical Hysterectomy for Cervical Carcinoma. Y.H. LEE, M.K. KIM, H.Y. MOON, G.O. CHONG, H.J. LEE, Y.S. LEE, J.Y. PARK, C.H. LEE, M.C. BAEK, D.G. HONG ( <i>Daegu, Republic of Korea</i> ) .....	337
A Comprehensive Method for Detecting Fusion Genes in Paediatric Brain Tumours. A. KONDO, Y. SHIMIZU, S. ADACHI, I. OGINO, M. SUZUKI, O. AKIYAMA, H. ARAI ( <i>Tokyo, Japan</i> ) .....	343

## Number 5, September-October

Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. E.A. MAZZIO, K.F.A. SOLIMAN ( <i>Tallahassee, FL, USA</i> ) .....	349
Copy Number Alterations in Tumor Genomes Deleting Antineoplastic Drug Targets Partially Compensated by Complementary Amplifications. H.V. TRAN, A.K. KIEMER, V. HELMS ( <i>Saarbruecken, Germany; Hanoi, Vietnam</i> ).....	365
Pyrosequencing Analysis of <i>MGMT</i> Promoter Methylation in Meningioma. I. PANAGOPOULOS, L. GORUNOVA, H. LESKE, P. NIEHUSMANN, L.E. JOHANNESSEN, J. STAURSETH, N. ØINO, T.R. MELING, S. HEIM, F. MICCI, P. BRANDAL ( <i>Oslo, Norway</i> ) .....	379
Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 ( <i>SLC18A1</i> ) in Lung Cancer. S. LEHRER, P.H. RHEINSTEIN ( <i>New York, NY; Severna Park, MD, USA</i> ) .....	387
Pull-down Assay on Streptavidin Beads and Surface Plasmon Resonance Chips for SWATH-MS-based Interactomics. J. MARYÁŠ, J. FAKTOR, L. ČÁPKOVÁ, P. MÜLLER, P. SKLÁDAL, P. BOUCHAL ( <i>Brno, Czech Republic</i> ) .....	395
Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan. T.-C. YUEH, Y.-W. HUNG, T.-C. SHIH, C.-N. WU, S.-C. WANG, Y.-L. LAI, S.-W. HSU, M.-H. WU, C.-K. FU, Y.-C. WANG, T.-W. KE, W.-S. CHANG, C.-W. TSAI, D.-T. BAU ( <i>Taichung; Taipei, Taiwan, ROC</i> ) .....	405
Indirect Down-regulation of Tumor-suppressive <i>let-7</i> Family MicroRNAs by <i>LMO1</i> in Neuroblastoma. N. SAEKI, A. SAITO, Y. SUGAYA, M. AMEMIYA, H. SASAKI ( <i>Okinawa; Tokyo, Japan</i> ).....	413
Review: Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. O. ROMANIDOU, V. KOTOULA, G. FOUNTZILAS ( <i>Thessaloniki, Greece</i> ) .....	421



**Number 6, November-December**

*MGMT* Gene Promoter Methylation Status – Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas. L.E. JOHANNESSEN, P. BRANDAL, T.Å. MYKLEBUST, S. HEIM, F. MICCI, I. PANAGOPOULOS (*Oslo; Ålesund, Norway*)..... 437

mRNA Expression of *CDK2AP1* in Human Breast Cancer: Correlation with Clinical and Pathological Parameters. R. GERA, L. MOKBEL, W.G. JIANG, K. MOKBEL (*London; Cardiff, UK*)..... 447

Novel Combination of Arsenic Trioxide (As<sub>2</sub>O<sub>3</sub>) Plus Resveratrol in Inducing Programmed Cell Death of Human Neuroblastoma SK-N-SH Cells. C.-M. YEN, C.-W. TSAI, W.-S. CHANG, Y.-C. YANG, Y.-W. HUNG, H.-T. LEE, C.-C. SHEN, M.-L. SHEU, J.-Y. WANG, C.-L. GONG, W.-Y. CHENG, D.-T. BAU (*Taichung, Taiwan, ROC*) ..... 453

Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. C. CHRISTODOULOU, G. OIKONOMOPOULOS, G.A. KOLIOU, I. KOSTOPOULOS, V. KOTOULA, M. BOBOS, G. PENTHEROUDAKIS, G. LAZARIDIS, M. SKONDRA, S. CHRISAFI, A. KOUTRAS, D. BAFALOUKOS, E. RAZIS, K. PAPADOPOULOU, P. PAPAKOSTAS, H.P. KALOFONOS, D. PECTASIDES, P. SKARLOS, K.T. KALOGERAS, G. FOUNTZILAS (*Piraeus; Athens; Thessaloniki; Ioannina; Patras, Greece*) ..... 461

Tumor Susceptibility Gene 101 Mediates Anoikis Resistance of Metastatic Thyroid Cancer Cells. K. SAHARAT, K. LIRDPRAPAMONGKOL, D. CHOKCHAICHAMNANKIT, C. SRISOMSAP, J. SVASTI, N.M. PARICHARTTANAKUL (*Bangkok, Thailand*) ..... 473

NOTUM Is Involved in the Progression of Colorectal Cancer. J.H. YOON, D. KIM, J. KIM, H. LEE, J. GHIM, B.J. KANG, P. SONG, P.-G. SUH, S.H. RYU, T.G. LEE (*Daegu; Pohang; Ulsan, Republic of Korea*)..... 485

Index 2018..... 499

## Subject Index

(Figures refer to page numbers)

- 2-Methoxyestradiol, mitochondrial biogenesis, osteosarcoma, sirtuin 3, succinate dehydrogenase, 73
- 3'-UTR, bladder cancer, cell-cycle and apoptosis pathways, miRNA, SNP, 67
- 4-HNE, LINE-1, bladder cancer, immunohistochemistry, oRF1p, oxidative stress, cancer progression, 143
- ABCB1, mantle cell lymphoma, bendamustine, resistance, MGST1, 213
- ACGH, CPT-K5, camptothecin resistance, karyotype, genomic instability, short tandem repeat, 91
- Adenoid cystic carcinoma, PP2A, pR55 $\beta$ , regulatory subunit,  $\beta$ -catenin, salivary gland, 53
- Adjuvant anti-metastatic therapy, bikunin, inter  $\alpha$ -trypsin inhibitors, *in vitro* and *in vivo* target validation, maspin, pigment-epithelial derived factor, protein substitution therapy, review, 225
- Advanced breast cancer, IGF-R, trastuzumab, hER2-positive breast cancer, hER2-negative breast cancer, 461
- African Americans, prostate cancer, RACGAP1, 185
- AML, genomics, NGS, mutation, 121
- Angiolipoma, cytogenetics, chromosome 13, deletion, *RBI* gene, 61
- Anoikis resistance, TSG101, metastasis, proteomics, thyroid cancer, 473
- Antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, epithelial ovarian cancer, extracellular matrix, locked nucleic acids, mesothelial cells, peritoneal dissemination, review, 1
- Apoptosis, arsenic trioxide, cytotoxicity, neuroblastoma, resveratrol, 453
- Arsenic trioxide, apoptosis, cytotoxicity, neuroblastoma, resveratrol, 453
- Ascites fluid, antisense oligonucleotides, epithelial mesenchymal transition, epithelial ovarian cancer, extracellular matrix, locked nucleic acids, mesothelial cells, peritoneal dissemination, review, 1
- B-catenin, PP2A, pR55 $\beta$ , regulatory subunit, adenoid cystic carcinoma, salivary gland, 53
- BCL2-inhibitor, gliomas, isocitrate dehydrogenases 1 and 2, IDH1, IDH2, myeloid leukemia, synthetic lethality, iDH-inhibitor, review, 421
- Bendamustine, mantle cell lymphoma, resistance, ABCB1, MGST1, 213
- Bikunin, adjuvant anti-metastatic therapy, inter  $\alpha$ -trypsin inhibitors, *in vitro* and *in vivo* target validation, maspin, pigment-epithelial derived factor, protein substitution therapy, review, 225
- Biomarker discovery, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, drug discovery, driver gene, gene-gene interaction, review, 41
- Biomarkers, NET, prognosis, lung neoplasms, review, 153
- Bladder cancer, 3'-UTR, cell-cycle and apoptosis pathways, miRNA, SNP, 67
- Bladder cancer, LINE-1, immunohistochemistry, oRF1p, 4-HNE, oxidative stress, cancer progression, 143
- BRAF* mutation, melanoma cells, SK-MEL-3, transcriptomic profile, histone deacetylase inhibitor, trichostatin A, MAPK/MEK/*BRAF* oncogenic pathway, mitotic arrest, 349
- BRAF*, paediatric brain tumours, KIAA1549, fusion gene, pyrosequencing, 343
- Breast cancer specimen, breast cancer, human breast cancer, tumour-suppressive function, tumour suppressor role, CDK2AP1, 447
- Breast cancer, human breast cancer, tumour-suppressive function, tumour suppressor role, breast cancer specimen, CDK2AP1, 447
- Camptothecin resistance, CPT-K5, karyotype, aCGH, genomic instability, short tandem repeat, 91
- Cancer classification, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- Cancer genome atlas, glioblastoma, survival, 273
- Cancer genome, copy number variation, drug target, chemoresistance, the Cancer Genome Atlas, 365
- Cancer progression, LINE-1, bladder cancer, immunohistochemistry, oRF1p, 4-HNE, oxidative stress, 143
- Cancer stem cells, ILK, EMT, chemotherapy, chemoresistance, colorectal cancer, 127
- Case-control study, colorectal cancer, genotype, *MDM2*, polymorphism, Taiwan, 405
- CDK2AP1, breast cancer, human breast cancer, tumour-suppressive function, tumour suppressor role, breast cancer specimen, 447
- Cell-cycle and apoptosis pathways, 3'-UTR, bladder cancer, miRNA, SNP, 67
- Cervical carcinoma, nerve-sparing surgery, proteomics, liquid chromatography-mass spectrometry, 337
- Chemoresistance, copy number variation, drug target, cancer genome, the Cancer Genome Atlas, 365
- Chemoresistance, ILK, EMT, chemotherapy, colorectal cancer, cancer stem cells, 127
- Chemotherapy, ILK, EMT, chemoresistance, colorectal cancer, cancer stem cells, 127
- ChIP-seq, neuroblastoma, pediatric cancer, LMO1, therapeutic targets, transcription regulator, 165
- Cholangiocarcinoma, hepatocellular, massively parallel sequencing, clones, 291
- Chromosome 12, spindle cell lipomas, pleomorphic lipomas, cytogenetics, chromosome 13, *RBI* gene, FOXO1 gene, HMGA2 gene, 193
- Chromosome 13, angiolipoma, cytogenetics, deletion, *RBI* gene, 61
- Chromosome 13, spindle cell lipomas, pleomorphic lipomas, cytogenetics, chromosome 12, *RBI* gene, FOXO1 gene, HMGA2 gene, 193
- Classifier, machine learning (ML), support vector machine

- (SVM), genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- Clones, hepatocellular, cholangiocarcinoma, massively parallel sequencing, 291
- Clonogenicity, neurocutaneous melanocytosis, MEK162, omipalisib, 239
- Colon cancer, DNA mismatch repair, proteins, puerto Ricans, 265
- Colonization of distinct organs, epithelial-mesenchymal transition (EMT), exosomes, metastasis-related *in vivo* models, mesenchymal-epithelial transition (MET), migration and invasion, tumor cell/stromal cell interactions, review, 17
- Colorectal cancer, genotype, *MDM2*, polymorphism, Taiwan, case-control study, 405
- Colorectal cancer, genotype, *MMP-7*, polymorphism, Taiwan, 207
- Colorectal cancer, ILK, EMT, chemotherapy, chemoresistance, cancer stem cells, 127
- Colorectal cancer, NOTUM, secretomics, migration, diagnosis, 485
- Copy number variation, drug target, chemoresistance, cancer genome, the Cancer Genome Atlas, 365
- Cowden syndrome, ganglioneuroma, *PTEN*, osteosarcoma, hamartoma, 115
- CPT-K5, camptothecin resistance, karyotype, aCGH, genomic instability, short tandem repeat, 91
- Cytogenetics, angioliopoma, chromosome 13, deletion, *RBI* gene, 61
- Cytogenetics, spindle cell lipomas, pleomorphic lipomas, chromosome 13, chromosome 12, *RBI* gene, *FOXO1* gene, *HMGA2* gene, 193
- Cytotoxicity, apoptosis, arsenic trioxide, neuroblastoma, resveratrol, 453
- Dasatinib, mTOR, hIF-1 $\alpha$ , head and neck squamous cell carcinoma, drug resistance, nilotinib, erlotinib, gefitinib, 175
- Deletion, angioliopoma, cytogenetics, chromosome 13, *RBI* gene, 61
- Diagnosis, NOTUM, secretomics, colorectal cancer, migration, 485
- Diagnosis, pancreatic ductal adenocarcinoma, microRNAs, plasma, miR-21-5p, prognosis, 321
- Digital PCR, DNA methylation, heterogeneously methylated epialleles, leukemia, prostate cancer cells, 299
- DNA methylation, digital PCR, heterogeneously methylated epialleles, leukemia, prostate cancer cells, 299
- DNA mismatch repair, proteins, colon cancer, Puerto Ricans, 265
- Driver gene, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, gene-gene interaction, review, 41
- Drug discovery, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, driver gene, gene-gene interaction, review, 41
- Drug resistance, mTOR, hIF-1 $\alpha$ , head and neck squamous cell carcinoma, nilotinib, dasatinib, erlotinib, gefitinib, 175
- Drug target, copy number variation, chemoresistance, cancer genome, the Cancer Genome Atlas, 365
- DUI145, prostate cancer, metastasis, mS-based proteomics, proteogeomics, 279
- EGFR, solid-pseudo-papillary, neoplasm, L861Q, pancreas, 201
- EMT, ILK, chemotherapy, chemoresistance, colorectal cancer, cancer stem cells, 127
- Epithelial mesenchymal transition, antisense oligonucleotides, ascites fluid, epithelial ovarian cancer, extracellular matrix, locked nucleic acids, mesothelial cells, peritoneal dissemination, review, 1
- Epithelial ovarian cancer, antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, extracellular matrix, locked nucleic acids, mesothelial cells, peritoneal dissemination, review, 1
- Epithelial to mesenchymal transition, gastric cancer, *FGFR1*, peritoneal dissemination, 313
- Epithelial-mesenchymal transition (EMT), colonization of distinct organs, exosomes, metastasis-related *in vivo* models, mesenchymal-epithelial transition (MET), migration and invasion, tumor cell/stromal cell interactions, review, 17
- Erlotinib, mTOR, hIF-1 $\alpha$ , head and neck squamous cell carcinoma, drug resistance, nilotinib, dasatinib, gefitinib, 175
- Exosomes, colonization of distinct organs, epithelial-mesenchymal transition (EMT), metastasis-related *in vivo* models, mesenchymal-epithelial transition (MET), migration and invasion, tumor cell/stromal cell interactions, review, 17
- Extracellular matrix, antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, epithelial ovarian cancer, locked nucleic acids, mesothelial cells, peritoneal dissemination, review, 1
- Fanconi anemia, sepantronium bromide, transcriptome, YM-155, 249
- FGFR1*, gastric cancer, peritoneal dissemination, epithelial to mesenchymal transition, 313
- FOXO1* gene, spindle cell lipomas, pleomorphic lipomas, cytogenetics, chromosome 13, chromosome 12, *RBI* gene, *HMGA2* gene, 193
- Fusion gene, paediatric brain tumours, *BRAF*, KIAA1549, pyrosequencing, 343
- Ganglioneuroma, cowden syndrome, *PTEN*, osteosarcoma, hamartoma, 115
- Gastric cancer, *FGFR1*, peritoneal dissemination, epithelial to mesenchymal transition, 313
- Gefitinib, mTOR, hIF-1 $\alpha$ , head and neck squamous cell carcinoma, drug resistance, nilotinib, dasatinib, erlotinib, 175
- Gene expression, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- Gene selection, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41

- Gene-gene interaction, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, review, 41
- Genomic instability, CPT-K5, camptothecin resistance, karyotype, aCGH, short tandem repeat, 91
- Genomics, AML, NGS, mutation, 121
- Genomics, machine learning (ML), support vector machine (SVM), classifier, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- Genotype, colorectal cancer, *MDM2*, polymorphism, Taiwan, case-control study, 405
- Genotype, colorectal cancer, MMP-7, polymorphism, Taiwan, 207
- Glioblastoma, *MGMT* gene promoter, methylation, pyrosequencing, methylation-specific PCR, overall survival, 437
- Glioblastoma, survival, cancer genome atlas, 273
- Gliomas, isocitrate dehydrogenases 1 and 2, IDH1, IDH2, myeloid leukemia, synthetic lethality, iDH-inhibitor, bCL2-inhibitor, review, 421
- Hamartoma, cowden syndrome, ganglioneuroma, *PTEN*, osteosarcoma, 115
- HDACs expression, ovarian cancer, leptin, leptin receptors blocker, 329
- Head and neck squamous cell carcinoma, mTOR, hIF-1 $\alpha$ , drug resistance, nilotinib, dasatinib, erlotinib, gefitinib, 175
- Hepatocellular, cholangiocarcinoma, massively parallel sequencing, clones, 291
- HER2-negative breast cancer, IGF-R, trastuzumab, advanced breast cancer, hER2-positive breast cancer, 461
- HER2-positive breast cancer, IGF-R, trastuzumab, advanced breast cancer, hER2-negative breast cancer, 461
- Heterogeneously methylated epialleles, digital PCR, DNA methylation, leukemia, prostate cancer cells, 299
- HIF-1 $\alpha$ , mTOR, head and neck squamous cell carcinoma, drug resistance, nilotinib, dasatinib, erlotinib, gefitinib, 175
- Histone deacetylase inhibitor, melanoma cells, SK-MEL-3, transcriptomic profile, trichostatin A, *BRAF* mutation, MAPK/MEK/*BRAF* oncogenic pathway, mitotic arrest, 349
- HMGA2 gene, spindle cell lipomas, pleomorphic lipomas, cytogenetics, chromosome 13, chromosome 12, *RBI* gene, FOXO1 gene, 193
- Human breast cancer, breast cancer, tumour-suppressive function, tumour suppressor role, breast cancer specimen, CDK2AP1, 447
- IDH-inhibitor, gliomas, isocitrate dehydrogenases 1 and 2, IDH1, IDH2, myeloid leukemia, synthetic lethality, bCL2-inhibitor, review, 421
- IDH1, gliomas, isocitrate dehydrogenases 1 and 2, IDH2, myeloid leukemia, synthetic lethality, iDH-inhibitor, bCL2-inhibitor, review, 421
- IDH2, gliomas, isocitrate dehydrogenases 1 and 2, IDH1, myeloid leukemia, synthetic lethality, iDH-inhibitor, bCL2-inhibitor, review, 421
- IGF-R, trastuzumab, advanced breast cancer, hER2-positive breast cancer, hER2-negative breast cancer, 461
- ILK, EMT, chemotherapy, chemoresistance, colorectal cancer, cancer stem cells, 127
- Immunohistochemistry, LINE-1, bladder cancer, oRF1p, 4-HNE, oxidative stress, cancer progression, 143
- In vitro* and *in vivo* target validation, adjuvant anti-metastatic therapy, bikunin, inter  $\alpha$ -trypsin inhibitors, maspin, pigment-epithelial derived factor, protein substitution therapy, review, 225
- Inter  $\alpha$ -trypsin inhibitors, adjuvant anti-metastatic therapy, bikunin, *in vitro* and *in vivo* target validation, maspin, pigment-epithelial derived factor, protein substitution therapy, review, 225
- Isocitrate dehydrogenases 1 and 2, gliomas, IDH1, IDH2, myeloid leukemia, synthetic lethality, iDH-inhibitor, bCL2-inhibitor, review, 421
- Karyotype, CPT-K5, camptothecin resistance, aCGH, genomic instability, short tandem repeat, 91
- Kernel function, machine learning (ML), support vector machine (SVM), classifier, genomics, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- KIAA1549, paediatric brain tumours, *BRAF*, fusion gene, pyrosequencing, 343
- L861Q, solid-pseudo-papillary, neoplasm, EGFR, pancreas, 201
- LC-SWATH-MS/MS, pull-down assay, PDLIM2, protein-protein interactions, SPR, 395
- Leptin receptors blocker, ovarian cancer, leptin, hDACs expression, 329
- Leptin, ovarian cancer, leptin receptors blocker, hDACs expression, 329
- Let-7*, neuroblastoma, pediatric cancer, LMO1, microRNA, 413
- Leukemia, digital PCR, DNA methylation, heterogeneously methylated epialleles, prostate cancer cells, 299
- LINE-1, bladder cancer, immunohistochemistry, oRF1p, 4-HNE, oxidative stress, cancer progression, 143
- Liquid chromatography–mass spectrometry, cervical carcinoma, nerve-sparing surgery, proteomics, 337
- LMO1, neuroblastoma, pediatric cancer, chIP-seq, therapeutic targets, transcription regulator, 165
- LMO1, neuroblastoma, pediatric cancer, microRNA, *let-7*, 413
- Locked nucleic acids, antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, epithelial ovarian cancer, extracellular matrix, mesothelial cells, peritoneal dissemination, review, 1
- Lung cancer, pembrolizumab, nivolumab, the Cancer Genome Atlas, *SLC18A1*, 387
- Lung neoplasms, NET, biomarkers, prognosis, review, 153
- Machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- Mantle cell lymphoma, bendamustine, resistance, ABCB1, *MGST1*, 213
- MAPK/MEK/*BRAF* oncogenic pathway, melanoma cells, SK-

- MEL-3, transcriptomic profile, histone deacetylase inhibitor, trichostatin A, *BRAF* mutation, mitotic arrest, 349
- Maspin, adjuvant anti-metastatic therapy, bikunin, inter  $\alpha$ -trypsin inhibitors, *in vitro* and *in vivo* target validation, pigment-epithelial derived factor, protein substitution therapy, review, 225
- Massively parallel sequencing, hepatocellular, cholangiocarcinoma, clones, 291
- MDM2*, colorectal cancer, genotype, polymorphism, Taiwan, case-control study, 405
- MEK162, clonogenicity, neurocutaneous melanocytosis, omipalisib, 239
- Melanoma cells, SK-MEL-3, transcriptomic profile, histone deacetylase inhibitor, trichostatin A, *BRAF* mutation, MAPK/MEK/*BRAF* oncogenic pathway, mitotic arrest, 349
- Meningioma, *MGMT* promoter, methylation, pyrosequencing, predictive value, 379
- Mesenchymal-epithelial transition (MET), colonization of distinct organs, epithelial-mesenchymal transition (EMT), exosomes, metastasis-related *in vivo* models, migration and invasion, tumor cell/stromal cell interactions, review, 17
- Mesothelial cells, antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, epithelial ovarian cancer, extracellular matrix, locked nucleic acids, peritoneal dissemination, review, 1
- Metastasis-related *in vivo* models, colonization of distinct organs, epithelial-mesenchymal transition (EMT), exosomes, mesenchymal-epithelial transition (MET), migration and invasion, tumor cell/stromal cell interactions, review, 17
- Metastasis, prostate cancer, mS-based proteomics, proteogeomics, DU145, 279
- Metastasis, TSG101, anoikis resistance, proteomics, thyroid cancer, 473
- Methylation-specific PCR, *MGMT* gene promoter, methylation, pyrosequencing, glioblastoma, overall survival, 437
- Methylation, meningioma, *MGMT* promoter, pyrosequencing, predictive value, 379
- Methylation, *MGMT* gene promoter, pyrosequencing, methylation-specific PCR, glioblastoma, overall survival, 437
- MGMT* gene promoter, methylation, pyrosequencing, methylation-specific PCR, glioblastoma, overall survival, 437
- MGMT* promoter, meningioma, methylation, pyrosequencing, predictive value, 379
- MGST1, mantle cell lymphoma, bendamustine, resistance, ABCB1, 213
- MicroRNA, neuroblastoma, pediatric cancer, LMO1, *let-7*, 413
- MicroRNAs, pancreatic ductal adenocarcinoma, plasma, miR-21-5p, diagnosis, prognosis, 321
- Migration and invasion, colonization of distinct organs, epithelial-mesenchymal transition (EMT), exosomes, metastasis-related *in vivo* models, mesenchymal-epithelial transition (MET), tumor cell/stromal cell interactions, review, 17
- Migration, NOTUM, secretomics, colorectal cancer, diagnosis, 485
- MiR-21-5p, pancreatic ductal adenocarcinoma, microRNAs, plasma, diagnosis, prognosis, 321
- MiRNA, 3'-UTR, bladder cancer, cell-cycle and apoptosis pathways, SNP, 67
- Mitochondrial biogenesis, 2-methoxyestradiol, osteosarcoma, sirtuin 3, succinate dehydrogenase, 73
- Mitotic arrest, melanoma cells, SK-MEL-3, transcriptomic profile, histone deacetylase inhibitor, trichostatin A, *BRAF* mutation, MAPK/MEK/*BRAF* oncogenic pathway, 349
- MMP-7, colorectal cancer, genotype, polymorphism, Taiwan, 207
- MS-based proteomics, prostate cancer, metastasis, proteogeomics, DU145, 279
- MTOR, hIF-1 $\alpha$ , head and neck squamous cell carcinoma, drug resistance, nilotinib, dasatinib, erlotinib, gefitinib, 175
- Mutation, AML, genomics, NGS, 121
- Myeloid leukemia, gliomas, isocitrate dehydrogenases 1 and 2, IDH1, IDH2, synthetic lethality, iDH-inhibitor, bCL2-inhibitor, review, 421
- Neoplasm, solid-pseudo-papillary, EGFR, L861Q, pancreas, 201
- Nerve-sparing surgery, cervical carcinoma, proteomics, liquid chromatography-mass spectrometry, 337
- NET, biomarkers, prognosis, lung neoplasms, review, 153
- Neuroblastoma, apoptosis, arsenic trioxide, cytotoxicity, resveratrol, 453
- Neuroblastoma, pediatric cancer, LMO1, chIP-seq, therapeutic targets, transcription regulator, 165
- Neuroblastoma, pediatric cancer, LMO1, microRNA, *let-7*, 413
- Neurocutaneous melanocytosis, clonogenicity, MEK162, omipalisib, 239
- NGS, AML, genomics, mutation, 121
- Nilotinib, mTOR, hIF-1 $\alpha$ , head and neck squamous cell carcinoma, drug resistance, dasatinib, erlotinib, gefitinib, 175
- Nivolumab, pembrolizumab, lung cancer, the Cancer Genome Atlas, *SLC18A1*, 387
- NOTUM, secretomics, colorectal cancer, migration, diagnosis, 485
- Omipalisib, clonogenicity, neurocutaneous melanocytosis, MEK162, 239
- ORF1p, LINE-1, bladder cancer, immunohistochemistry, 4-HNE, oxidative stress, cancer progression, 143
- Osteosarcoma, 2-methoxyestradiol, mitochondrial biogenesis, sirtuin 3, succinate dehydrogenase, 73
- Osteosarcoma, cowden syndrome, ganglioneuroma, *PTEN*, hamartoma, 115
- Ovarian cancer, leptin, leptin receptors blocker, hDACs expression, 329
- Overall survival, *MGMT* gene promoter, methylation, pyrosequencing, methylation-specific PCR, glioblastoma, 437
- Oxidative stress, LINE-1, bladder cancer, immunohistochemistry, oRF1p, 4-HNE, cancer progression, 143
- Paediatric brain tumours, *BRAF*, KIAA1549, fusion gene, pyrosequencing, 343

- Pancreas, solid-pseudo-papillary, neoplasm, EGFR, L861Q, 201
- Pancreatic ductal adenocarcinoma, microRNAs, plasma, miR-21-5p, diagnosis, prognosis, 321
- PDLIM2, LC-SWATH-MS/MS, pull-down assay, protein-protein interactions, SPR, 395
- Pediatric cancer, neuroblastoma, LMO1, chIP-seq, therapeutic targets, transcription regulator, 165
- Pediatric cancer, neuroblastoma, LMO1, microRNA, *let-7*, 413
- Pembrolizumab, nivolumab, lung cancer, the Cancer Genome Atlas, *SLC18A1*, 387
- Peritoneal dissemination, antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, epithelial ovarian cancer, extracellular matrix, locked nucleic acids, mesothelial cells, review, 1
- Peritoneal dissemination, gastric cancer, *FGFR1*, epithelial to mesenchymal transition, 313
- Pigment-epithelial derived factor, adjuvant anti-metastatic therapy, bikunin, inter  $\alpha$ -trypsin inhibitors, *in vitro* and *in vivo* target validation, maspin, protein substitution therapy, review, 225
- Plasma, pancreatic ductal adenocarcinoma, microRNAs, miR-21-5p, diagnosis, prognosis, 321
- Pleomorphic lipomas, spindle cell lipomas, cytogenetics, chromosome 13, chromosome 12, *RBI* gene, *FOXO1* gene, *HMG2A* gene, 193
- Polymorphism, colorectal cancer, genotype, *MDM2*, Taiwan, case-control study, 405
- Polymorphism, colorectal cancer, genotype, *MMP-7*, Taiwan, 207
- PP2A, pR55 $\beta$ , regulatory subunit,  $\beta$ -catenin, adenoid cystic carcinoma, salivary gland, 53
- PR55 $\beta$ , PP2A, regulatory subunit,  $\beta$ -catenin, adenoid cystic carcinoma, salivary gland, 53
- Predictive value, meningioma, *MGMT* promoter, methylation, pyrosequencing, 379
- Prognosis, NET, biomarkers, lung neoplasms, review, 153
- Prognosis, pancreatic ductal adenocarcinoma, microRNAs, plasma, miR-21-5p, diagnosis, 321
- Prostate cancer cells, digital PCR, DNA methylation, heterogeneously methylated epialleles, leukemia, 299
- Prostate cancer, african Americans, *RACGAP1*, 185
- Prostate cancer, metastasis, mS-based proteomics, proteogeomics, DU145, 279
- Protein substitution therapy, adjuvant anti-metastatic therapy, bikunin, inter  $\alpha$ -trypsin inhibitors, *in vitro* and *in vivo* target validation, maspin, pigment-epithelial derived factor, review, 225
- Protein-protein interactions, LC-SWATH-MS/MS, pull-down assay, PDLIM2, SPR, 395
- Proteins, DNA mismatch repair, colon cancer, puertoricans, 265
- Proteogeomics, prostate cancer, metastasis, mS-based proteomics, DU145, 279
- Proteomics, cervical carcinoma, nerve-sparing surgery, liquid chromatography-mass spectrometry, 337
- Proteomics, TSG101, anoikis resistance, metastasis, thyroid cancer, 473
- PTEN*, cowden syndrome, ganglioneuroma, osteosarcoma, hamartoma, 115
- Puertoricans, DNA mismatch repair, proteins, colon cancer, 265
- Pull-down assay, LC-SWATH-MS/MS, PDLIM2, protein-protein interactions, SPR, 395
- Pyrosequencing, meningioma, *MGMT* promoter, methylation, predictive value, 379
- Pyrosequencing, *MGMT* gene promoter, methylation, methylation-specific PCR, glioblastoma, overall survival, 437
- Pyrosequencing, paediatric brain tumours, *BRAF*, *KIAA1549*, fusion gene, 343
- RACGAP1*, prostate cancer, african Americans, 185
- RBI* gene, angioliipoma, cytogenetics, chromosome 13, deletion, 61
- RBI* gene, spindle cell lipomas, pleomorphic lipomas, cytogenetics, chromosome 13, chromosome 12, *FOXO1* gene, *HMG2A* gene, 193
- Regulatory subunit, PP2A, pR55 $\beta$ ,  $\beta$ -catenin, adenoid cystic carcinoma, salivary gland, 53
- Resistance, mantle cell lymphoma, bendamustine, *ABCB1*, *MGST1*, 213
- Resveratrol, apoptosis, arsenic trioxide, cytotoxicity, neuroblastoma, 453
- Review, adjuvant anti-metastatic therapy, bikunin, inter  $\alpha$ -trypsin inhibitors, *in vitro* and *in vivo* target validation, maspin, pigment-epithelial derived factor, protein substitution therapy, 225
- Review, antisense oligonucleotides, ascites fluid, epithelial mesenchymal transition, epithelial ovarian cancer, extracellular matrix, locked nucleic acids, mesothelial cells, peritoneal dissemination, 1
- Review, colonization of distinct organs, epithelial-mesenchymal transition (EMT), exosomes, metastasis-related *in vivo* models, mesenchymal-epithelial transition (MET), migration and invasion, tumor cell/stromal cell interactions, 17
- Review, gliomas, isocitrate dehydrogenases 1 and 2, *IDH1*, *IDH2*, myeloid leukemia, synthetic lethality, *iDH*-inhibitor, *bCL2*-inhibitor, 421
- Review, machine learning (ML), support vector machine (SVM), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, 41
- Review, NET, biomarkers, prognosis, lung neoplasms, 153
- Salivary gland, PP2A, pR55 $\beta$ , regulatory subunit,  $\beta$ -catenin, adenoid cystic carcinoma, 53
- Secretomics, *NOTUM*, colorectal cancer, migration, diagnosis, 485
- Sepantronium bromide, transcriptome, Fanconi anemia, YM-155, 249
- Short tandem repeat, CPT-K5, camptothecin resistance, karyotype, aCGH, genomic instability, 91
- Sirtuin 3, 2-methoxyestradiol, mitochondrial biogenesis, osteosarcoma, succinate dehydrogenase, 73
- SK-MEL-3, melanoma cells, transcriptomic profile, histone

- deacetylase inhibitor, trichostatin A, *BRAF* mutation, MAPK/MEK/*BRAF* oncogenic pathway, mitotic arrest, 349
- SLC18A1*, pembrolizumab, nivolumab, lung cancer, the Cancer Genome Atlas, 387
- SNP, 3'-UTR, bladder cancer, cell-cycle and apoptosis pathways, miRNA, 67
- Solid-pseudo-papillary, neoplasm, EGFR, L861Q, pancreas, 201
- Spindle cell lipomas, pleomorphic lipomas, cytogenetics, chromosome 13, chromosome 12, *RBI* gene, *FOXO1* gene, *HMGA2* gene, 193
- SPR, LC-SWATH-MS/MS, pull-down assay, *PDLIM2*, protein-protein interactions, 395
- Succinate dehydrogenase, 2-methoxyestradiol, mitochondrial biogenesis, osteosarcoma, sirtuin 3, 73
- Support vector machine (SVM), machine learning (ML), classifier, genomics, kernel function, gene expression, cancer classification, gene selection, biomarker discovery, drug discovery, driver gene, gene-gene interaction, review, 41
- Survival, glioblastoma, cancer genome atlas, 273
- Synthetic lethality, gliomas, isocitrate dehydrogenases 1 and 2, *IDH1*, *IDH2*, myeloid leukemia, *iDH*-inhibitor, *bCL2*-inhibitor, review, 421
- Taiwan, colorectal cancer, genotype, *MDM2*, polymorphism, case-control study, 405
- Taiwan, colorectal cancer, genotype, *MMP-7*, polymorphism, 207
- The Cancer Genome Atlas, copy number variation, drug target, chemoresistance, cancer genome, 365
- The Cancer Genome Atlas, pembrolizumab, nivolumab, lung cancer, *SLC18A1*, 387
- Therapeutic targets, neuroblastoma, pediatric cancer, LMO1, chIP-seq, transcription regulator, 165
- Thyroid cancer, TSG101, anoikis resistance, metastasis, proteomics, 473
- Transcription regulator, neuroblastoma, pediatric cancer, LMO1, chIP-seq, therapeutic targets, 165
- Transcriptome, sepantonium bromide, Fanconi anemia, YM-155, 249
- Transcriptomic profile, melanoma cells, SK-MEL-3, histone deacetylase inhibitor, trichostatin A, *BRAF* mutation, MAPK/MEK/*BRAF* oncogenic pathway, mitotic arrest, 349
- Trastuzumab, IGF-R, advanced breast cancer, hER2-positive breast cancer, hER2-negative breast cancer, 461
- Trichostatin A, melanoma cells, SK-MEL-3, transcriptomic profile, histone deacetylase inhibitor, *BRAF* mutation, MAPK/MEK/*BRAF* oncogenic pathway, mitotic arrest, 349
- TSG101, anoikis resistance, metastasis, proteomics, thyroid cancer, 473
- Tumor cell/stromal cell interactions, colonization of distinct organs, epithelial-mesenchymal transition (EMT), exosomes, metastasis-related *in vivo* models, mesenchymal-epithelial transition (MET), migration and invasion, review, 17
- Tumour suppressor role, breast cancer, human breast cancer, tumour-suppressive function, breast cancer specimen, *CDK2AP1*, 447
- Tumour-suppressive function, breast cancer, human breast cancer, tumour suppressor role, breast cancer specimen, *CDK2AP1*, 447
- YM-155, sepantonium bromide, transcriptome, Fanconi anemia, 249

## Authors Index

(Figures refer to page numbers)

- Abbas M, 185  
 Abuel-Haija M, 115  
 Adachi S, 343  
 Adam MA, 153  
 Aderhold C, 175  
 Akiyama O, 343  
 Al Diffalha S, 201  
 Amemiya M, 165, 413  
 Andersen HK, 193  
 Andersen K, 61, 193  
 Antonia T, 265  
 Arai H, 343  
 Bae YJ, 291  
 Baek MC, 337  
 Bafaloukos D, 461  
 Barone G, 73  
 Basu D, 239  
 Bau D-T, 207, 405, 453  
 Bauer B, 239  
 Bertolini DM, 239  
 Birk R, 175  
 Birzele F, 1, 17, 225  
 Bjerkehagen B, 61, 193  
 Bobos M, 461  
 Boonla C, 143  
 Bouchal P, 395  
 Brandal P, 379, 437  
 Bravou V, 127  
 Brinkmann U, 17  
 Brzozowski MR, 239  
 Cai N, 41  
 Čápková L, 395  
 Centeno BA, 201  
 Champeris Tsaniras S, 127  
 Chang W-S, 207, 405, 453  
 Cheng W-Y, 453  
 Chinen Y, 213  
 Chokchaichamnankit D, 473  
 Chong GO, 337  
 Chrisafi S, 461  
 Christodoulou C, 461  
 Chu H, 67  
 Coppola D, 115, 201, 265  
 Dickopf S, 17  
 Du M, 67  
 Dunston GM, 185  
 Dutil J, 265  
 Eguchi H, 313  
 Eisler SA, 73  
 Elhag R, 249  
 Faktor J, 395  
 Fiedor E, 329  
 Fountzilias G, 421, 461  
 Friedemann M, 299  
 Fu C-K, 207, 405  
 Fujibayashi Y, 213  
 Gablo N, 321  
 Gera R, 447  
 Ghim J, 485  
 Giannopoulou E, 127  
 Goering W, 143  
 Gong C-L, 453  
 Gorska-Ponikowska M, 73  
 Gorunova L, 61, 193, 379  
 Gregoraszczyk EL, 329  
 Gutiérrez S, 265  
 Harpole D, 153  
 Heim S, 61, 193, 379, 437  
 Helms V, 365  
 Hermanova M, 321  
 Hintermair C, 17  
 Hlavsa J, 321  
 Hoehl RM, 239  
 Hoffmann MJ, 143  
 Hong DG, 337  
 Horiike S, 213  
 Hsu S-W, 405  
 Huang S, 41  
 Hung Y-W, 207, 405, 453  
 Hussaini MO, 121  
 Ishibashi K, 53  
 Ishii K, 53  
 Ito S, 313  
 Jakobsen A-K, 91  
 Jandek C, 299  
 Jeon J, 291  
 Jeon JM, 279  
 Jiang WG, 447  
 Jindatip D, 143  
 Johannessen LE, 379, 437  
 Kala Z, 321  
 Kalofonos HP, 127, 461  
 Kalogeras KT, 461  
 Kamata Y, 53  
 Kanaan YM, 185  
 Kang BJ, 485  
 Karasek P, 321  
 Ke T-W, 405  
 Khakoo Y, 239  
 Kiemer AK, 365  
 Kim D, 485  
 Kim J, 485  
 Kim MK, 337  
 Kim SJ, 279  
 Kiss I, 321  
 Kittles RA, 185  
 Kiyoshima T, 53  
 Kjeldsen E, 91  
 Knudsen BR, 91  
 Kobayashi T, 213  
 Kodera Y, 313  
 Koliou GA, 461  
 Kollmorgen G, 1, 17  
 Komatsuzaki R, 165  
 Komrokji R, 121  
 Kondo A, 343  
 Kostopoulos I, 461  
 Kotoula V, 421, 461  
 Koutras A, 461  
 Kramer B, 175  
 Kuban-Jankowska A, 73  
 Kumamaru W, 53  
 Kurashige J, 313  
 Kuroda J, 213  
 Kuroda Y, 313  
 Kwon OK, 279  
 Lai Y-L, 207, 405  
 Lancet J, 121  
 Lange BS, 299  
 Lazaridis G, 461  
 Lee CH, 337  
 Lee E-J, 291  
 Lee H, 485  
 Lee HJ, 337  
 Lee H-T, 453  
 Lee S, 279  
 Lee TG, 485  
 Lee YH, 337  
 Lee Y-M, 207  
 Lee YS, 337  
 Lehrer S, 273, 387  
 Leske H, 379  
 Lewis CA, 249  
 Li H-T, 207  
 Lirdprapamongkol K, 473  
 Liu H, 67  
 Lo Bosco G, 73  
 Lobmaier I, 61, 193  
 Lopez C, 115, 265  
 Lund-Iversen M, 193  
 Ma G, 67  
 Maegawa S, 213  
 Maeng L-S, 291  
 Malafa MP, 201, 265  
 Maroulis I, 127  
 Maryáš J, 395  
 Mason TE, 185  
 Masuda T, 313  
 Matsumura-Kimoto Y, 213  
 Mazzio EA, 249, 349  
 Meling TR, 379  
 Menschikowski M, 299  
 Micci F, 379, 437  
 Mimori K, 313  
 Mirza A-S, 121  
 Mizuno Y, 213  
 Mizutani S, 213  
 Mokbel K, 447  
 Mokbel L, 447  
 Moon HY, 337  
 Mori Y, 53  
 Moris D, 153  
 Müller P, 395  
 Myklebust TÅ, 437  
 Na A-Y, 279  
 Nagoshi H, 213  
 Nakano H, 53  
 Narandes S, 41  
 Neill KG, 201  
 Niehusmann P, 379  
 Nielsen CJF, 91  
 Nikou S, 127  
 Nopora A, 1  
 Ntanasis-Stathopoulos I, 153  
 Nussberger S, 73  
 Ogino I, 343  
 Ohyama Y, 53  
 Oikonomopoulos G, 461  
 Øino N, 379  
 Ono H, 165  
 Padron E, 121  
 Panagopoulos I, 61, 193, 379, 437  
 Papadopoulou K, 461  
 Papakostas P, 461  
 Paricharttanakul NM, 473  
 Park JY, 337  
 Patel JR, 239  
 Pectasides D, 461  
 Pei J-S, 207  
 Pena L, 115  
 Penthroudakis G, 461  
 Penzuti Pacheco P, 41  
 Perricone U, 73  
 Pimratana C, 143  
 Polit M, 175  
 Prochazka V, 321  
 Qian J, 67  
 Razis E, 461  
 Reverón D, 265  
 Reyes-Múgica M, 239  
 Rheinstein PH, 273, 387  
 Richter S, 299  
 Ricks-Santi LJ, 185  
 Romanidou O, 421  
 Rosenzweig KE, 273



Rotter N, 175	Skarlos P, 461	Taraviras S, 127	Wijitsettakul U, 143
Roy A, 91	Skládal P, 395	Tesauro C, 91	Wilson BD, 185
Ryu SH, 485	Skondra M, 461	Theocharis S, 153	Wu C-N, 207, 405
Saeki N, 165, 413	Slaby O, 321	Thiem D, 299	Wu M-H, 207, 405
Saharat K, 473	Soliman KF, 249, 349	Tiefenthaler G, 225	Xu W, 41, 67
Saito A, 165, 413	Song J, 121	Tong N, 67	Yamada T, 53
Saito T, 313	Song P, 485	Tran HV, 365	Yanagihara K, 165
Salgado CM, 239	Srisomsap C, 473	Tsai C-W, 207, 405, 453	Yang CJ, 153
Saller J, 201	Staurseth J, 379	Tsilimigras DI, 153	Yang Y-C, 453
Sanpavat A, 143	Stougaard M, 91	Tsoumas D, 127	Yen C-M, 453
Sasaki H, 165, 413	Sugaya Y, 165, 413	Tsukamoto T, 213	Yen S-T, 207
Sayegh ZE, 265	Sugiyama G, 53	Vychytilova-Faltejskova P, 321	Yoon JH, 485
Schulz WA, 143	Suh P-G, 485	Wang J-Y, 453	Yoon N, 291
Shao J, 67	Sumida T, 53	Wang M, 67	Yoon YC, 291
Shen C-C, 453	Sung E, 279	Wang S-C, 405	Yuan L, 67
Sheu M-L, 453	Suttorp M, 299	Wang W, 67	Yueh T-C, 207, 405
Shih T-C, 405	Suzuki A, 53	Wang Y, 41	Zabec J, 239
Shimizu D, 313	Suzuki M, 343	Wang Y-C, 405	Zajda K, 329
Shimizu Y, 343	Svasti J, 473	Weidle UH, 1, 17, 225	Zhang Q, 67
Shimura Y, 213	Takimoto-Shimomura T, 213	Whongsiri P, 143	Zhang Z, 67
Sirinian C, 127	Taniwaki M, 213		Zolota V, 127

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org), [www.cgp.iiarjournals.org](http://www.cgp.iiarjournals.org)

**Publication Data:** CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly online-only and open access through High Wire Press, Stanford, USA. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

**Copyright:** Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence and reprint orders should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 2295053389, e-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org) (Editorial Office); [editor@iiar-anticancer.org](mailto:editor@iiar-anticancer.org) (Managing Editor).

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: [genomics.proteomics@utoronto.ca](mailto:genomics.proteomics@utoronto.ca)

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.